Fonterra and Nestlé will sell their Dairy Partners Americas (DPA) Brazil joint venture to French dairy company Lactalis for $133 million, subject to closing transaction adjustments.
The deal is expected to be completed by mid-2023.
The sale is aligned with the two companies' strategy of prioritizing its New Zealand milk pool.
According to Fonterra CEO Miles Hurrell, the sale of DPA Brazil allows us they prioritize their resources to the businesses that are core to our strategy.
DPA Brazil has been up for sale since January 2020 but the pandemic delayed any possible transaction.
To produce and market dairy goods across Latin America, Fonterra and Nestlé formed the joint venture in 2003. DPA shifted its emphasis to Brazil and chilled dairy in 2014.
Currently, Fonterra owns 51 percent of the JV, while Nestlé owns 49 percent.
DPA markets brands including Nestlé, Chamyto, Ninho, and Chandelle in Brazil. It runs two operations, employs about 1,300 people, and has two locations.


SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand
Trump, Canada Reach Gordie Howe Bridge Deal Ahead of July 27 Opening
Japanese Yen Rises as Pension Fund Plan and BOJ Rate Hike Bets Weigh on Dollar
Dollar Rises as Middle East Conflict Fuels Inflation and Rate Hike Fears
European Regulators Clash With U.S. Treasury Over Private Credit Transparency
Yes, government influences wages – but not just in the way you might think
Muji Owner Ryohin Keikaku Stock Soars After Raising Full-Year Earnings Forecast
Disaster or digital spectacle? The dangers of using floods to create social media content
Iraq PM Visits Washington as U.S. Oil, Gas Deals Take Center Stage
Gold Price Climbs Over 1% as Dollar Weakens, Fed Rate Debate and Iran Tensions Remain in Focus
Debate over H-1B visas shines spotlight on US tech worker shortages
Time to buy local: war fuel price shocks reveal the folly of a long food supply chain
Booked to travel through the Middle East? Here’s why you shouldn’t cancel your flight
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 



